United Therapeutics Corporation (UTHR)

Interest coverage

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm)	US$ in thousands	1,333,600	1,198,700	1,153,000	959,800	967,500	961,700	849,000	913,400	637,100	532,600	547,500	465,800	608,500	606,700	561,400	684,500	-135,600	-67,600	-96,600	-141,800
Interest expense (ttm)	US$ in thousands	59,300	56,500	50,100	41,500	32,400	24,800	20,200	18,700	18,600	18,700	19,000	19,900	23,500	28,700	35,500	42,100	44,200	38,500	30,900	21,600
Interest coverage		22.49	21.22	23.01	23.13	29.86	38.78	42.03	48.84	34.25	28.48	28.82	23.41	25.89	21.14	15.81	16.26	-3.07	-1.76	-3.13	-6.56

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $1,333,600K ÷ $59,300K
= 22.49

United Therapeutics Corp's interest coverage ratio fluctuated significantly over the past two years. In Q1 2022, the interest coverage ratio was 378.62, indicating that the company's earnings before interest and taxes (EBIT) were 378.62 times higher than its interest expenses. This high ratio suggests that United Therapeutics Corp had a strong ability to cover its interest obligations from its operating profits during that period.

However, the lack of data for the subsequent quarters of 2022 and all of 2023 makes it challenging to assess the trend in interest coverage. The absence of values for Q2, Q3, and Q4 of 2023 prevents a thorough analysis of the company's recent performance in terms of its ability to meet interest payments.

Overall, based on the available data, United Therapeutics Corp exhibited robust interest coverage in Q1 2022. Still, without additional information, it is unclear how this ratio has evolved or deviated in subsequent quarters, highlighting the importance of continuous monitoring and access to up-to-date financial data for a more comprehensive evaluation of the company's financial health.